市场见解

2 small-cap ASX shares with an edge over rivals

An expert picks a pair of smaller businesses that are doing all the right things to grow into a larger company.
The post 2 small-cap ASX shares with an edge over rivals appeared first on The Motley Fool Australia. –

Up until earlier this month, the S&P/ASX Small Ordinaries (ASX: XSO) had gained 30% in 12 months.

That amazing run has moderated somewhat after the market dip in the past week but you would still gladly take a 24.6% gain any year of your life.

And, of course, we’re always reminded that all the successful S&P/ASX 100 [XTO] (INDEXASX: XTO) companies were once small caps. Over time, they grew into their now-mammoth valuations.

But there is inherently more risk in backing smaller businesses. Much can go wrong, as much as it can go right.

So it’s interesting to hear when experts pick out some small-cap ASX shares that they think will grow into the next darlings.

It’s all about scale for small caps

Australian Ethical head of domestic equities Mike Murray told a Livewire video that in the small-cap world, the key is to find companies that will scale well.

“It’s just the nature of the beast that some of those industries scale better than others,” he said.

“We tend to find that product-style businesses with that degree of intellectual property are quite scalable, particularly if they’ve got a global market.”

One company he currently likes, Mach7 Technologies Ltd (ASX: M7T), is at “the intersection of healthcare and technology”.

According to Murray, it operates in a similar area to the far-larger Pro Medicus Limited (ASX: PME).

“Mach7 really grew out of a company that specialised in archiving the images that come out of radiology practices in hospitals,” he said.

“And increasingly it’s moved into actually the software around the viewing of those images, which is where Pro Medicus operates.”

Since the transition, Mach7 has won a few “very big” contracts, according to Murray.

“They’re generating a nice rate of growth and you don’t pay the multiples that you pay for Pro Medicus,” he said.

“So that’s an example of a company where we think we’re not paying over the top and it’s a smaller company, so it’s got quite a long runway of growth ahead of it.”

Health insurance is back

After decades of dropping numbers, the private health insurance industry this year has actually seen a rise in Australians signing up.

That’s why Murray reckons NIB Holdings Limited (ASX: NHF) is not just a “boring” insurance stock.

“It’s actually a very innovative company that has been diversifying out of health insurance,” he said.

“Some of the things they’ve been doing include a joint venture called Honeysuckle Health. It’s really a data science play and it’s really all about developing new programs to help people manage their health better and investing in prevention.”

Prevention of health problems benefits both the customer and the insurer, as it reduces future payouts for expensive treatments.

“It helps our system which has some affordability problems.”

The post 2 small-cap ASX shares with an edge over rivals appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of August 16th 2021

More reading

NIB (ASX:NHF) share price lower despite ACCC authorisation
Here are 3 reasons why Pro Medicus (ASX:PME) is a great ASX share to own
2 growing small cap ASX shares to watch

Top brokers name 3 ASX shares to sell today

Why BlueBet, Fortescue, Hansen, & Pro Medicus shares are sinking

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended MACH7 FPO and Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended MACH7 FPO and NIB Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

随时随地,交易世界!

移动APP平台,拥有 12 个市场的 50,000 多种全球上市证券(全球市值超过 70%),直接在您的 Android 或 iOS 设备上即可操作。

与独有的交易理念和投资分析工具相结合,帮助您在我们 12 个全球市场中的几乎所有金融工具上找到可操作的见解,从而帮助您优化交易策略。

推荐给您的朋友

向您的朋友推荐Monex并赠予他们免费使用我们交易工具的机会

我们尊重您的隐私,只会向您的朋友发送一封邮件 

与您的朋友分享

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!